Key Highlights
- FDA grants Fast Track designation to Diakonos Oncology’s dendritic cell vaccine (DCV) for pancreatic cancer.
- Dr. Daniel D. Von Hoff joins Diakonos’ Scientific Advisory Board, bringing extensive expertise in pancreatic cancer.
- Positive Phase 1 trial results for Diakonos’ glioblastoma vaccine, improving 12-month survival rates.
- Diakonos’ DCV technology leverages patients’ dendritic cells to initiate targeted immune responses without genetic modification.
Source: Business Wire
Notable Quotes
- “This second FDA Fast Track designation of our autologous dendritic cell vaccines for pancreatic cancer is another acknowledgement of the incredible potential of this innovative immunotherapy for treating the most deadly cancers.” — Mike Wicks, CEO at Diakonos Oncology
- “Diakonos’s unique dendritic cell vaccine has shown encouraging results in treating glioblastoma, a terrible disease with few effective treatments. Pancreatic cancer patients also need additional treatment options.” — Dr. Daniel D. Von Hoff, Distinguished Professor at TGen
SoHC's Take
The FDA’s Fast Track designation for Diakonos Oncology’s dendritic cell vaccine (DCV) represents a pivotal development in the fight against pancreatic cancer, a notoriously aggressive and lethal disease. This recognition underscores the potential of Diakonos’ innovative immunotherapy approach, which has already shown promise in treating glioblastoma. The inclusion of Dr. Daniel D. Von Hoff on the Scientific Advisory Board adds significant expertise and insight, likely accelerating the clinical development of this promising therapy. Diakonos’ focus on utilizing a patient’s own immune cells without genetic modification not only simplifies the manufacturing process but also makes the treatment more accessible and cost-effective, potentially transforming cancer treatment paradigms.
